158 related articles for article (PubMed ID: 22926332)
1. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*.
Xuan W; Wu B; Chen C; Chen B; Zhang W; Xu D; Bin J; Liao Y
Crit Care Med; 2012 Nov; 40(11):3026-33. PubMed ID: 22926332
[TBL] [Abstract][Full Text] [Related]
2. Detrimental effect of fractalkine on myocardial ischaemia and heart failure.
Xuan W; Liao Y; Chen B; Huang Q; Xu D; Liu Y; Bin J; Kitakaze M
Cardiovasc Res; 2011 Dec; 92(3):385-93. PubMed ID: 21840883
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway.
Kanamori H; Takemura G; Goto K; Tsujimoto A; Ogino A; Takeyama T; Kawaguchi T; Watanabe T; Morishita K; Kawasaki M; Mikami A; Fujiwara T; Fujiwara H; Seishima M; Minatoguchi S
Am J Pathol; 2013 Mar; 182(3):701-13. PubMed ID: 23274061
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats.
Lin JF; Lin SM; Chih CL; Nien MW; Su HH; Hu BR; Huang SS; Tsai SK
Life Sci; 2008 Aug; 83(9-10):313-7. PubMed ID: 18639559
[TBL] [Abstract][Full Text] [Related]
5. A glass of wine: how good is good? The resveratrol lesson*.
Iervasi G; Forini F; Sabatino L
Crit Care Med; 2012 Nov; 40(11):3098-9. PubMed ID: 23080448
[No Abstract] [Full Text] [Related]
6. Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart.
Wu X; Sagave J; Rutkovskiy A; Haugen F; Baysa A; Nygård S; Czibik G; Dahl CP; Gullestad L; Vaage J; Valen G
Life Sci; 2014 Mar; 97(2):145-54. PubMed ID: 24398041
[TBL] [Abstract][Full Text] [Related]
7. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure.
Husberg C; Nygård S; Finsen AV; Damås JK; Frigessi A; Oie E; Waehre A; Gullestad L; Aukrust P; Yndestad A; Christensen G
J Mol Cell Cardiol; 2008 Aug; 45(2):261-9. PubMed ID: 18585734
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Sanganalmath SK; Barta J; Takeda N; Kumamoto H; Dhalla NS
Can J Physiol Pharmacol; 2008 Apr; 86(4):180-9. PubMed ID: 18418427
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism.
Sung MM; Das SK; Levasseur J; Byrne NJ; Fung D; Kim TT; Masson G; Boisvenue J; Soltys CL; Oudit GY; Dyck JR
Circ Heart Fail; 2015 Jan; 8(1):128-37. PubMed ID: 25394648
[TBL] [Abstract][Full Text] [Related]
10. Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction.
Burstein B; Maguy A; Clément R; Gosselin H; Poulin F; Ethier N; Tardif JC; Hébert TE; Calderone A; Nattel S
J Pharmacol Exp Ther; 2007 Dec; 323(3):916-23. PubMed ID: 17875610
[TBL] [Abstract][Full Text] [Related]
11. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.
Bousette N; Pottinger J; Ramli W; Ohlstein EH; Dhanak D; Douglas SA; Giaid A
Peptides; 2006 Nov; 27(11):2919-26. PubMed ID: 16919371
[TBL] [Abstract][Full Text] [Related]
12. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice.
Montecucco F; Braunersreuther V; Lenglet S; Delattre BM; Pelli G; Buatois V; Guilhot F; Galan K; Vuilleumier N; Ferlin W; Fischer N; Vallée JP; Kosco-Vilbois M; Mach F
Eur Heart J; 2012 Aug; 33(15):1964-74. PubMed ID: 21606075
[TBL] [Abstract][Full Text] [Related]
13. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.
Abbate A; Salloum FN; Vecile E; Das A; Hoke NN; Straino S; Biondi-Zoccai GG; Houser JE; Qureshi IZ; Ownby ED; Gustini E; Biasucci LM; Severino A; Capogrossi MC; Vetrovec GW; Crea F; Baldi A; Kukreja RC; Dobrina A
Circulation; 2008 May; 117(20):2670-83. PubMed ID: 18474815
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
Gu XS; Wang ZB; Ye Z; Lei JP; Li L; Su DF; Zheng X
Genet Mol Res; 2014 Jan; 13(1):323-35. PubMed ID: 24535859
[TBL] [Abstract][Full Text] [Related]
15. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling.
Dahl CP; Husberg C; Gullestad L; Waehre A; Damås JK; Vinge LE; Finsen AV; Ueland T; Florholmen G; Aakhus S; Halvorsen B; Aukrust P; Oie E; Yndestad A; Christensen G
Circ Heart Fail; 2009 Nov; 2(6):624-32. PubMed ID: 19919988
[TBL] [Abstract][Full Text] [Related]
16. Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models.
Dong M; Ding W; Liao Y; Liu Y; Yan D; Zhang Y; Wang R; Zheng N; Liu S; Liu J
Eur J Pharmacol; 2015 Jan; 746():186-97. PubMed ID: 25449040
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats.
Shen M; Jia GL; Wang YM; Ma H
Vascul Pharmacol; 2006 Aug; 45(2):122-6. PubMed ID: 16765650
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
Westenbrink BD; Ruifrok WP; Voors AA; Tilton RG; van Veldhuisen DJ; Schoemaker RG; van Gilst WH; de Boer RA
Cardiovasc Res; 2010 Jul; 87(1):30-9. PubMed ID: 20139114
[TBL] [Abstract][Full Text] [Related]
19. DITPA, a thyroid hormone analog, reduces infarct size and attenuates the inflammatory response following myocardial ischemia.
Abohashem-Aly AA; Meng X; Li J; Sadaria MR; Ao L; Wennergren J; Fullerton DA; Raeburn CD
J Surg Res; 2011 Dec; 171(2):379-85. PubMed ID: 21658725
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
J Pharmacol Exp Ther; 2003 Apr; 305(1):97-105. PubMed ID: 12649357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
